Expert Opin Emerg Drugs. 2012 Mar;17(1):1-4. doi: 10.1517/14728214.2012.667800. Epub 2012 Mar 6.
In 2007, Bosma et. al provided a comprehensive review of emerging therapies for the acute respiratory distress syndrome (ARDS), a condition which continues to carry a mortality rate of greater than 30%. Over the past several years, the development of novel and effective therapeutic agents for ARDS remains disappointing, and unfortunately, no recent therapeutic interventions have demonstrated a clear benefit. Herein, the results of several of these early and late phase clinical trials are reviewed, the majority of which address known maladaptive processes that have been deemed critical in ARDS pathophysiology. Based on the ongoing futility of current therapeutic models to yield effective therapies, it is speculated whether or not novel treatment paradigms, which address distinctly different aspects of this disease paradigm, may be warranted.
2007 年，Bosma 等人对急性呼吸窘迫综合征（ARDS）的新兴治疗方法进行了全面综述，这种疾病的死亡率仍然超过 30%。在过去的几年中，ARDS 的新型有效治疗药物的开发仍然令人失望，不幸的是，最近没有任何治疗干预措施显示出明显的益处。本文综述了其中几项早期和晚期临床试验的结果，这些临床试验主要针对被认为在 ARDS 病理生理学中至关重要的已知适应性不良过程。鉴于当前治疗模式在产生有效治疗方法方面的持续无效性，可以推测是否需要新型治疗模式来解决该疾病模式的明显不同方面。
